Table 5.
Comparison of the plasma concentrations of the soluble co-stimulatory, co-inhibitory and dual-activity immune checkpoints measured in the plasma of the cohort of early breast cancer patients post-NAC and post-surgery.
| ICM | Post-NAC (n=72) | Post-Surgery (n=72) | p value | |
|---|---|---|---|---|
| Median pg/mL (95%CI) | Median pg/mL (95%CI) | |||
| Co-stimulatory | CD27 | 5351.47 | 5427.68 | 0.8105 |
| (4678.25 – 5894.37) | (4411.67 – 6317.06) | |||
| CD28 | 44277.76 | 50058.18 | 0.5705 | |
| (38319.44 – 51220.42) | (34830.52 – 64706.44) | |||
| CD40 | 2030.72 | 2054.12 | 0.6203 | |
| (1792.50 – 2199.04) | (1820.74 – 2383.79) | |||
| ICOS | 26586.28 | 29746.46 | 0.3751 | |
| (20912.88 – 31335.04) | (24270.58 – 33438.89) | |||
| GITR | 4035.98 | 4434,89 | 0.9777 | |
| (3198.29 – 5204.35) | (3354.37 – 6046.58) | |||
| GITRL | 5339.99 | 5927.89 | 0.5226 | |
| (4728.24 – 6121.00) | (4860.76 – 7008.59) | |||
| CD86 | 9922.61 | 12439.80 | 0.2276 | |
| (7890.94 – 11990.77) | (9566.36 – 14837.24) | |||
| CD80 | 3048.74 | 3611.23 | 0.6459 | |
| (2522.82 – 3520.25) | (2754.67 – 4138.41) | |||
| Co-inhibitory | PD-1 | 13350.55 | 15076.64 | 0.3102 |
| (10537.37 – 15491.33) | (12077.71 – 19383.37) | |||
| PD-L1 | 4794.97 | 5215.05 | 0.8667 | |
| (4162.41 – 5731.71) | (4239.88 – 5969.17) | |||
| CTLA-4 | 598.20 | 687.76 | 0.8292 | |
| (472.91 – 768.78) | (550.45 – 828.91) | |||
| TIM-3 | 9975.90 | 9615.77 | 1.0000 | |
| (8793.62 – 10515.70) | (8440.15 – 10984.92) | |||
| LAG-3 | 464880.70 | 500133.40 | 0.5992 | |
| (309218.5 – 580137.6) | (466624.6 – 500748.6) | |||
| BTLA | 9987.98 | 12777.20 | 0.3217 | |
| (8255.35 – 12554.33) | (9507.29 – 15003.63) | |||
| Dual | TLR-2 | 33837.86 | 37042.86 | 0.7782 |
| (28228.61 - 39571.02) | (29069.20 – 45880.29) | |||
| HVEM | 4047.29 | 3950.36 | 0.6259 | |
| (3610.92 – 4445.29) | (3611.92 – 4381.72) |